<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4. Discussion</segment>
<segment id="2" parent="1002" relname="span">In this study , exposure to ERAV ,</segment>
<segment id="3" parent="1003" relname="same_unit">as determined by serological testing ,</segment>
<segment id="4" parent="1004" relname="span">was associated with respiratory disease , loss of training days and failure</segment>
<segment id="5" parent="4" relname="purpose">to race in young racehorses .</segment>
<segment id="6" parent="1008" relname="attribution">Monthly screening indicated</segment>
<segment id="7" parent="1008" relname="span">that the majority of two-year-old horses were exposed to ERAV during the three months</segment>
<segment id="8" parent="7" relname="circumstance">after entering the yard .</segment>
<segment id="9" parent="1011" relname="span">The clinical signs</segment>
<segment id="10" parent="9" relname="elaboration">that resulted in an interruption to training</segment>
<segment id="11" parent="1010" relname="same_unit">were primarily observed</segment>
<segment id="12" parent="1012" relname="joint">after the horses had been in the yard for several weeks</segment>
<segment id="13" parent="1012" relname="joint">and were being prepared for their first race .</segment>
<segment id="14" parent="1014" relname="span">The susceptibility of young horses to rhinitis virus infection</segment>
<segment id="15" parent="1015" relname="joint">when moved to a new environment</segment>
<segment id="16" parent="1016" relname="same_unit">and starting to comingle with other horses</segment>
<segment id="17" parent="1016" relname="same_unit">has been reported previously .</segment>
<segment id="18" parent="1018" relname="span">In a seven-year serological study of racehorses in Japan , 69 % of horses</segment>
<segment id="19" parent="1019" relname="joint">that seroconverted to ERAV were two years of age</segment>
<segment id="20" parent="21" relname="attribution">and Black et al. reported</segment>
<segment id="21" parent="1020" relname="span">that 43 % of horses seroconverted to ERAV within 7 months of entering a training stable in Australia .</segment>
<segment id="22" parent="1023" relname="attribution">A previous study in a training yard in Ireland indicated</segment>
<segment id="23" parent="1023" relname="joint">that ERAV infection was largely confined to two-year-old horses</segment>
<segment id="24" parent="1023" relname="joint">and was most prevalent in late winter and spring .</segment>
<segment id="25" parent="26" relname="attribution">However , we believe</segment>
<segment id="26" parent="1025" relname="span">that this is the first investigation of the association between ERAV infection with interrupted training and failure to race .</segment>
<segment id="27" parent="1024" relname="joint">Over 55 % of the two-year-olds in the study seroconverted to ERAV in May and June</segment>
<segment id="28" parent="1024" relname="joint">and none of them raced at that time .</segment>
<segment id="29" parent="1024" relname="joint">In fact , only 29 % of the two-year-olds raced in their first season .</segment>
<segment id="30" parent="31" relname="attribution">The results of this study suggest</segment>
<segment id="31" parent="1030" relname="span">that the importance of ERAV in the interruption of training programmes for young horses may be underestimated .</segment>
<segment id="32" parent="1032" relname="span">Acute febrile respiratory disease</segment>
<segment id="33" parent="32" relname="elaboration">following ERAV infection has been reported previously .</segment>
<segment id="34" parent="1034" relname="span">In an experimental study , ERAV-inoculated ponies developed respiratory tract disease</segment>
<segment id="35" parent="1035" relname="span">characterized by pyrexia , nasal discharge , adventitious lung sounds , and enlarged mandibular lymph nodes ,</segment>
<segment id="36" parent="35" relname="elaboration">which corresponded with an increase in antibody titres against the virus .</segment>
<segment id="37" parent="1037" relname="span">The clinical signs</segment>
<segment id="38" parent="1038" relname="joint">observed during this study were associated with the seroconversions</segment>
<segment id="39" parent="1038" relname="joint">and there was no evidence of other viral infections .</segment>
<segment id="40" parent="41" relname="concession">ERAV may have been the primary cause of the respiratory disease and subsequent training loss ,</segment>
<segment id="41" parent="1040" relname="span">but it is more likely that the virus was a contributory factor in a multifactorial disorder .</segment>
<segment id="42" parent="1043" relname="span">The serology tests</segment>
<segment id="43" parent="42" relname="elaboration">used in this study are sensitive and specific ,</segment>
<segment id="44" parent="1042" relname="span">but it is possible that other less common viruses , such as adenovirus and coronavirus , or even as-yet unidentified equine viruses , may have played a role .</segment>
<segment id="45" parent="1039" relname="joint">Previous studies have demonstrated the complexity of poor performance syndrome in Thoroughbred racehorses</segment>
<segment id="46" parent="1039" relname="joint">and that bacteria are more common</segment>
<segment id="47" parent="1039" relname="joint">and may be aetiologically more important than viruses .</segment>
<segment id="48" parent="1048" relname="joint">Unfortunately , the possible role of bacterial infection as a cofactor was not investigated in this study</segment>
<segment id="49" parent="1048" relname="joint">and the statistically significant association of ERAV with failure to race during the study period does not conclusively demonstrate causation .</segment>
<segment id="50" parent="1050" relname="span">However , it is essential to determine which infectious agents are prevalent in populations</segment>
<segment id="51" parent="1051" relname="span">that suffer interruption</segment>
<segment id="52" parent="1052" relname="span">to training as a first step</segment>
<segment id="53" parent="52" relname="elaboration">in assessing their true impact .</segment>
<segment id="54" parent="1054" relname="span">Lack of previous exposure to ERAV and stress</segment>
<segment id="55" parent="54" relname="elaboration">associated with the change of environment and intensive training may have contributed to disease susceptibility .</segment>
<segment id="56" parent="1056" relname="span">In contrast to the two-year-old horses , no seroconversions to ERAV were observed in the three-year-old horses</segment>
<segment id="57" parent="1057" relname="span">â€”</segment>
<segment id="58" parent="1058" relname="joint">they remained free of any signs of respiratory disease</segment>
<segment id="59" parent="1058" relname="joint">and raced successfully throughout the study period .</segment>
<segment id="60" parent="1060" relname="span">The seroconversion to ERAV in the four-year-old horse and the reinfection of two of the younger horses were not associated with clinical signs or reduced performance .</segment>
<segment id="61" parent="1062" relname="attribution">Experimental studies have indicated</segment>
<segment id="62" parent="1062" relname="joint">that ERAV infection stimulated a protective response</segment>
<segment id="63" parent="1062" relname="joint">and that reinfection is asymptomatic .</segment>
<segment id="64" parent="65" relname="attribution">The serology results indicate</segment>
<segment id="65" parent="1064" relname="span">that ERAV was circulating in the yard throughout the six month study period .</segment>
<segment id="66" parent="1066" relname="contrast">The dynamics of ERAV infection in horse populations are poorly understood</segment>
<segment id="67" parent="1066" relname="contrast">but virus persists in horses even in the presence of high levels of antibodies .</segment>
<segment id="68" parent="1067" relname="span">ERAV can be isolated from the blood for a few days post infection and from the nasopharynx and faeces for up to a month .</segment>
<segment id="69" parent="1069" relname="span">Studies in the USA , Ireland and Australia detected ERAV in post-race urine samples at frequencies of 17 % , 29 % and 23 % , respectively ,</segment>
<segment id="70" parent="1070" relname="span">which led to a suggestion</segment>
<segment id="71" parent="70" relname="elaboration">that the persistent presence of ERAV in urine may contribute to its maintenance in training yards .</segment>
<segment id="72" parent="1072" relname="background">ERBV was not detected in urine .</segment>
<segment id="73" parent="1072" relname="span">During this study period , only one horse seroconverted to ERBV .</segment>
<segment id="74" parent="1074" relname="span">This was consistent with an earlier study in Ireland</segment>
<segment id="75" parent="74" relname="elaboration">in which ERAV was found to be more commonly detected than ERBV .</segment>
<segment id="76" parent="1073" relname="joint">Co-circulation of ERAV and ERBV was also reported previously .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1005" relname="background"/>
<group id="1003" type="multinuc" parent="2" relname="circumstance"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="multinuc" parent="1001" relname="span"/>
<group id="1006" type="span" parent="1005" relname="joint"/>
<group id="1007" type="span" parent="1006" relname="span"/>
<group id="1008" type="span" parent="1007" relname="span"/>
<group id="1009" type="span" parent="1007" relname="elaboration"/>
<group id="1010" type="multinuc" parent="1009" relname="span"/>
<group id="1011" type="span" parent="1010" relname="same_unit"/>
<group id="1012" type="multinuc" parent="1010" relname="circumstance"/>
<group id="1014" type="span" parent="1005" relname="joint"/>
<group id="1015" type="multinuc" parent="14" relname="circumstance"/>
<group id="1016" type="multinuc" parent="1015" relname="joint"/>
<group id="1017" type="multinuc" parent="1005" relname="joint"/>
<group id="1018" type="span" parent="1017" relname="sequence"/>
<group id="1019" type="multinuc" parent="18" relname="elaboration"/>
<group id="1020" type="span" parent="1019" relname="joint"/>
<group id="1021" type="multinuc" parent="1017" relname="sequence"/>
<group id="1022" type="span" parent="1021" relname="contrast"/>
<group id="1023" type="multinuc" parent="1022" relname="span"/>
<group id="1024" type="multinuc" parent="1021" relname="contrast"/>
<group id="1025" type="span" parent="1024" relname="joint"/>
<group id="1030" type="span" parent="1024" relname="joint"/>
<group id="1032" type="span" parent="1024" relname="joint"/>
<group id="1034" type="span" parent="1024" relname="joint"/>
<group id="1035" type="span" parent="34" relname="elaboration"/>
<group id="1036" type="span" parent="1024" relname="joint"/>
<group id="1037" type="span" parent="1039" relname="preparation"/>
<group id="1038" type="multinuc" parent="37" relname="elaboration"/>
<group id="1039" type="multinuc" parent="1036" relname="span"/>
<group id="1040" type="span" parent="1039" relname="joint"/>
<group id="1042" type="span" parent="1039" relname="joint"/>
<group id="1043" type="span" parent="44" relname="concession"/>
<group id="1047" type="multinuc" parent="1039" relname="joint"/>
<group id="1048" type="multinuc" parent="1047" relname="contrast"/>
<group id="1049" type="multinuc" parent="1047" relname="contrast"/>
<group id="1050" type="span" parent="1049" relname="joint"/>
<group id="1051" type="span" parent="50" relname="elaboration"/>
<group id="1052" type="span" parent="51" relname="purpose"/>
<group id="1054" type="span" parent="1049" relname="joint"/>
<group id="1056" type="span" parent="1049" relname="joint"/>
<group id="1057" type="span" parent="56" relname="elaboration"/>
<group id="1058" type="multinuc" parent="57" relname="elaboration"/>
<group id="1059" type="span" parent="1049" relname="joint"/>
<group id="1060" type="span" parent="1059" relname="span"/>
<group id="1061" type="span" parent="60" relname="elaboration"/>
<group id="1062" type="multinuc" parent="1061" relname="span"/>
<group id="1063" type="multinuc" parent="1060" relname="elaboration"/>
<group id="1064" type="span" parent="1063" relname="joint"/>
<group id="1065" type="multinuc" parent="1063" relname="joint"/>
<group id="1066" type="multinuc" parent="1065" relname="joint"/>
<group id="1067" type="span" parent="1065" relname="joint"/>
<group id="1068" type="span" parent="68" relname="elaboration"/>
<group id="1069" type="span" parent="1068" relname="span"/>
<group id="1070" type="span" parent="69" relname="elaboration"/>
<group id="1071" type="span" parent="1069" relname="elaboration"/>
<group id="1072" type="span" parent="1071" relname="span"/>
<group id="1073" type="multinuc" parent="73" relname="elaboration"/>
<group id="1074" type="span" parent="1073" relname="joint"/>
	</body>
</rst>
